Clinical conditions | HRV | Time domain | Frequency domain |
---|---|---|---|
Hemodialysis [6] | All-cause mortality: decreased HRV (HR 1.63 (95% CI 1.11–2.39), P = 0.014, I2 = 74.2%) (association)* | All-cause mortality: decreased SDANN (HR 1.03 (95% CI 1.01–1.05), P = 0.001, I2 = 21.8%) | All-cause mortality: decreased LF/HF ratio (HR 8.69 (95% CI 2.24–33.68), P = 0.002, I2 = 53.5%) |
CV mortality: decreased HRV (HR 1.07 (95% CI: 1.00–1.15), P = 0.045, I2 = 89.7%) (association)* | |||
Cancer (pancreatic cancer, breast cancer, advanced non-small cell lung cancer and mixed cancer types) [7] | Overall survival: between the higher HRV group and the lower HRV group (HR 0.70 (95% CI 0.60–0.82), P < 0.001, I2 = 27%) | ||
Unstable angina and preserved left ventricular function [8] | In‐hospital death: SDNNi < 39 ms (OR 4.99 (95% CI 1.18–21.1), P = 0.029) | In‐hospital death: LF < 15,7 ms (OR 4,94 (95% CI 1,16–20,9), P = 0,030); LF/HF ratio < 1.12 (OR 5.14 (95% CI 1.21–21.8), P = 0.026) | |
Congestive heart failure [9] | Cardiac events: VLF In (ms2) 6.24, (Chi-square), P = 0.01) | ||
Severe sepsis [10] | Survivors: SDNN value was significantly higher among survivors (SD 18.50 (IR 10.00–34.50)) as compared to non-survivors (SD 8.50 (IR 5.00–14.50), P = 0.003). SDNN (ms) (HR 0.937 (95% CI 0.883–0.995), P = 0.033) | ||
Finnish adult population [11] | Total mortality: HRV morning-evening (RH 1.08 (95% CI 1.03–1.13), P < 0.001); HRV morning day-by-day (RH 1.11 (95% CI 1.05–1.17), P < 0.001) Fatal and nonfatal CV events: HRV morning day-by-day (RH 1.11 (95% CI 1.05–1.17), P < 0.001) |